Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2016-11-08

Clinical Trial Update: Efficacy Study Exploring the Effect of Lu AE58054 as Augmentation Therapy in Patients With Schizophrenia [Phase 2]

View source ↗

Summary

Phase 2 efficacy study evaluating Lu AE58054 as augmentation therapy in schizophrenia has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Lu AE58054

Snippet

Sponsor: H. Lundbeck A/S | Conditions: Schizophrenia, Cognition | Phase 2 | Status: COMPLETED